These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33762119)

  • 1. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
    Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
    J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
    Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
    Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
    Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
    Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.
    Bownes LV; Julson JR; Quinn CH; Hutchins SC; Erwin MH; Markert HR; Stewart JE; Mroczek-Musulman E; Aye J; Yoon KJ; Ohlmeyer M; Beierle EA
    J Pediatr Surg; 2023 Jun; 58(6):1145-1154. PubMed ID: 36907775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.
    Julson JR; Quinn CH; Butey S; Erwin MH; Marayati R; Nazam N; Stewart JE; Beierle EA
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
    Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Markert HR; Easlick JL; Stewart JE; Crossman DK; Mroczek-Musulman E; Beierle EA
    Cancer Gene Ther; 2022 May; 29(5):558-572. PubMed ID: 33864024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
    Stafman LL; Williams AP; Marayati R; Aye JM; Stewart JE; Mroczek-Musulman E; Beierle EA
    PLoS One; 2019; 14(4):e0214469. PubMed ID: 30969990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.
    Stafman LL; Waldrop MG; Williams AP; Aye JM; Stewart JE; Mroczek-Musulman E; Yoon KJ; Whelan K; Beierle EA
    J Pediatr Surg; 2019 Jun; 54(6):1206-1213. PubMed ID: 30898394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.
    Stafman LL; Williams AP; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Beierle EA
    Transl Oncol; 2019 Feb; 12(2):200-208. PubMed ID: 30412911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cIAP1 in the effective suppression of chemotherapy‑resistant hepatoblastoma.
    Tsukada R; Nomura M; Ueno T; Okuyama H
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35211761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
    Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
    Eicher C; Dewerth A; Thomale J; Ellerkamp V; Hildenbrand S; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Br J Cancer; 2013 Feb; 108(2):334-41. PubMed ID: 23257893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nur77 inhibition of β-catenin expression mediates Hepatoblastoma progression and enhances cisplatin's therapeutic effect.
    Zhou J; Liu X; Yin H; Zhou Y; Xu Z; Zhou K; Li T; Fang Y; Shen Q
    Gene; 2024 May; 908():148292. PubMed ID: 38369247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma.
    Dewerth A; Wonner T; Lieber J; Ellerkamp V; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Pediatr Surg Int; 2012 Jun; 28(6):579-89. PubMed ID: 22526548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1.
    Canal F; Anthony E; Lescure A; Del Nery E; Camonis J; Perez F; Ragazzon B; Perret C
    BMC Cancer; 2015 Dec; 15():1020. PubMed ID: 26715116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
    Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
    Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a drug resistance model for hepatoblastoma.
    Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Int J Oncol; 2011 Feb; 38(2):447-54. PubMed ID: 21132272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.